Arbital Health’s Vision is to be the Neutral Adjudicator of Outcomes-Based Contracts, Helping Healthcare’s Shift to Value-Based Care

Santa Barbara Actuaries is a leading specialist in the design and measurement of value-based programs

$10 Million Series A Investment Led by Transformation Capital, with Participation by Shaper Capital, Healthy Ventures, and individual data and healthcare luminaries

SAN FRANCISCO, Jan. 4, 2024 — Arbital Health, a technology startup focused on accelerating the healthcare industry’s transition to value-based care, today announced the acquisition of Santa Barbara Actuaries, Inc. (SBA), and $10 million in Series A financing led by digital healthcare investor Transformation Capital. 

Arbital Health, co-founded by Travis May and Brian Overstreet, launched in November 2023 and recently announced its Leadership Team and Advisory Board, including former leaders of the FDA and VA, healthcare business leaders, and value-based care experts. Arbital Health is building technology to help companies design and measure outcome-based contracts, serving as a neutral third-party adjudicator to assess whether outcomes were fulfilled.

Santa Barbara Actuaries is a leading actuarial and healthcare consulting firm specializing in value-based care and data analytics solutions. The acquisition of Santa Barbara Actuaries by Arbital Health provides the company with a best-in-class value-based care actuarial team along with top-tier clients across the value-based care landscape.

“We are very excited to welcome the Santa Barbara Actuaries team to Arbital Health. SBA has established itself as a leading solutions provider for the entire value-based care ecosystem. Their stellar reputation for impartial analysis, statistical rigor, and best-in-class services and solutions are a key element to our mission to become the neutral, third-party utility for the design, measurement, and adjudication of outcome-based contracts in U.S. healthcare,” said Brian M. Overstreet, President & CEO of Arbital Health. “I am also pleased to welcome Transformation Capital as the lead investor in our $10 million Series A financing. Solving the misalignment of incentives in healthcare is one of the most important challenges of our era, and we are thrilled to have assembled an incredible set of investors, advisors, and team for the journey ahead.”

Dr. Ian Duncan FSA, MAAA, President of Santa Barbara Actuaries said, “Since our founding, Santa Barbara Actuaries has been at the forefront of supporting value-based care by building one of the best actuarial teams and serving some of the most innovative clients. Arbital Health’s expertise in productizing and scaling healthcare technology platforms will enable us to bring better incentive alignment to all healthcare stakeholders via value-based care. This announcement stands as a testament to the talent, hard work, and innovation of the Santa Barbara Actuaries team.”

Arbital’s initial product offering will include the following:

• Value Assessment for Point Solution Health Vendors: Accurately quantify the economic value your healthcare intervention delivers and drive even higher ROI through leveraging Arbital’s predictive analytics for engagement optimization.
• Value Analysis for Payers, Including Employers and Health Plans: Understand the true economic value your employees and members are getting from the point solutions you have deployed.
• Actuarial Advisory: Through SBA’s differentiated expertise, Arbital Health will continue to provide a broad range of consulting services for risk-bearing organizations.

Investment Round

In addition to announcing the acquisition of Santa Barbara Actuaries, Arbital Health also completed its $10 million Series A financing, led by Transformation Capital. Other institutional investors in the funding round include Shaper Capital, Healthy Ventures, Flex Capital, and Underdog Labs. 

“We are excited to partner with Brian, Travis, and the Arbital Health team on their mission to create the neutral third-party utility for the design, measurement, and adjudication of value-based care,” said Scott Rosen, Partner at Transformation Capital. “We believe that Arbital Health’s unique approach, team, technology, and track record position it well to be a major force in this space for years to come.”

In conjunction with the acquisition and financing, Dr. Ian Duncan and Scott Rosen will both join Arbital Health’s Board of Directors to serve alongside Chairman Travis May and Brian Overstreet. Dr. Ian Duncan will also serve as Chief Actuary for Arbital Health.

About Arbital Health
Arbital Health’s vision is to become the neutral third-party adjudicator of outcomes-based contracts, unlocking and accelerating the $1 trillion shift to value-based care in the U.S. healthcare system. We aspire to be the trusted umpire adjudicating every outcome-based contract in healthcare, whether contracts are between life sciences companies and payers, payers and providers, or employers and digital health companies. We will make it simple to adjudicate contracts and unlock the trillion-dollar shift to value-based care in America. In doing so, we will help to solve healthcare’s biggest problem. For more information, and to explore career opportunities available, visit Arbital Health at https://www.arbitalhealth.com or follow on LinkedIn.

About Santa Barbara Actuaries
Santa Barbara Actuaries is an actuarial and healthcare consulting firm specializing in value-based contracting, predictive modeling, and data analytics. Dr. Ian Duncan FSA MAAA is the President and Founder of Santa Barbara Actuaries. Ian has extensive experience in care management program operations and evaluation. He has published over 80 peer-reviewed studies of care management program outcomes and associated predictive models. Ian is concurrently a Professor at UCSB and author of Healthcare Risk Adjustment and Predictive Modeling and Managing and Evaluating Healthcare Intervention Programs (Actex Publications). For more information visit www.sbactuaries.com.

About Transformation Capital
Transformation Capital is a digital health growth equity firm dedicated to supporting commercial stage companies focused on improving people’s health and the sustainability of the healthcare system. The firm was founded on the premise that investing in healthcare requires both a sophisticated understanding of the healthcare system, including the prevailing market forces and resulting opportunities, as well as deep connections with decision makers across key providers, payers and digital health innovators. Transformation Capital has invested in digital health companies across the ecosystem, including Datavant, Apree, Capital RX, Health Catalyst, Sword, Grow Therapy, Jeenie and Groups.

CONTACTS

Media Contact for Arbital Health and Santa Barbara Actuaries
Jesica Freeman
[email protected]

Media Contact for Transformation Capital
Melanie Albanese
[email protected]

SOURCE Arbital Health

Data from IDC reveals that XREAL commanded 51% market share of the AR market during Q3 2023, accounting for 58% of the year-over-year increased shipments in 2023 in the overall AR industry. Along with shipping up to 350,000 AR glasses to date, the XREAL Air series AR glasses are the best-seller on Amazon for the Smart Glasses category. These achievements not only underline the success of XREAL glasses, but also the increasing momentum of the XREAL spatial computing brand in the quickly growing consumer wearable display market. According to IDC, the worldwide AR market is forecasted to grow at a compound annual growth rate (CAGR) of 89% (2022A-2027E), and XREAL has achieved a CAGR (9M2021 to 9M2023) of 320% historically. As the global leader in consumer AR devices, XREAL’s AR glasses are a lightweight, more comfortable, more affordable alternative to Apple’s Vision Pro and Meta’s Quest 3. Packing in advanced optics and environment sensing technology, XREAL AR glasses are the ultimate spatial computing companion.

“Today we celebrate a major milestone on our journey to bring AR wearable displays to everyone around the world, revolutionizing how people experience everything from video games to movies and TV, in-car entertainment and displays, and how they work at their desks or on the go,” said Chi Xu, founder, and CEO at XREAL. “Having secured a major foothold in the global wearable display market, XREAL is now in a stronger position to embrace market momentum and reaffirm its position as the leading, best-selling AR glasses and spatial computing brand in the world today, who’s trajectory is outpacing the rest of the industry combined.”

Defining the Era of Wearable Displays and Future of Spatial Computing
Since the launch of Nreal Light in 2019 and XREAL Air, the first consumer AR glasses introduced to the world in 2022, the XREAL brand has continued to grow and thrive, quickly establishing itself as a leader in consumer AR device design and manufacturing. Today, XREAL Air series glasses give people a unique opportunity to experience a stunning virtual screen of up to 330-inches in a variety of everyday scenarios.

Featuring the latest Micro-OLED displays from Sony, XREAL Air 2 and Air 2 Pro were launched globally in October 2023, building on the success of the previous generation, to give the wearer a lighter, more comfortable experience. XREAL Air 2 series glasses also offer a superior viewing experience with improved brightness and color reproduction, higher pixel density, and an ultra-high contrast ratio, while debuting an improved audio and microphone system, and one-touch immersion control using XREAL Electrochromic Dimming (XREAL Air 2 Pro).

XREAL Air glasses are compatible with leading gaming and streaming entertainment devices including Microsoft Xbox, Sony PlayStation, Nintendo Switch, Valve Steam Deck, ASUS ROG Ally, iOS and Android devices, PCs, and Macs.

XREAL Air 2 and XREAL Air 2 Pro are available now in the US, Europe and Asia, and will come to more countries in 2024.

At CES 2024 in Las Vegas, XREAL will unveil its next iteration of spatial computing hardware and more details about its accompanying SDK for developers, rivaling the spatial capabilities of Apple’s Vision Pro and Meta’s Quest 3. XREAL promises more information at CES 2024.

Celebrating all of XREAL’s news during CES 2024, XREAL’s full catalog of products is on sale now at XREAL.com.

CONTACT: [email protected]

SOURCE XREAL

Premier Sports Apparel Company Positioned for Expansion in 2024

CHERRY HILL, N.J., Jan. 4, 2024 — Varlo Sports, a trailblazing company at the intersection of design and performance in the sports apparel industry, proudly announces the successful completion of its most recent seed funding round. This significant milestone ensures the company’s continued growth and operational excellence as it embarks on its next chapter in 2024.

Varlo Sports is thrilled to welcome prominent backers, including REI Co-op Path Ahead Ventures, a venture capital fund founded by the outdoor retailer. The $30 million fund aligns with Varlo’s commitment to excellence and innovation in the athletic performance apparel space.

Also co-leading this investment are Todd Leff, former CEO and current Chairman of the Board of Hand and Stone Massage and Facial Spas, and John Cassimatis, former Management Consulting executive, entrepreneur, and Board Advisor to growth companies.

“This investment is not just a testament to the potential of Varlo,” said Varlo Sports CEO, Soj Jibowu. “It is a recognition of the passion and dedication that drives our team to create cutting-edge performance apparel that empowers all humans to conquer the goals of tomorrow.”

The seed funding will help fuel innovation by expanding product lines, and reaching a broader audience that shares the company’s ethos of pushing boundaries and pursuing excellence.

For media inquiries, please contact:
Will McQuilkin
Senior Account Executive
Varlo Sports
[email protected]
415-887-9325

About Varlo Sports:

Established in 2019, Varlo Sports has emerged as a formidable presence in triathlon, cycling, and multisport, championing inclusivity by crafting high-performance apparel for athletes of all sizes, genders, religions, and abilities. This commitment has cultivated a devoted following among athletes seeking premium gear that inspires their limitless potential to break barriers and push further than yesterday.

SOURCE Varlo Sports

NEW YORK, Jan. 4, 2024 — UrbanStems, the premier modern floral gifting company, announces that it has secured $5 million in Series C extension funding from existing investors. The capital fuels the company’s growth strategy as it expands same-day delivery service to new cities across the U.S. The round was led by SWaN & Legend and DF Enterprises with additional funding from existing investors. The announcement comes alongside the company’s same-day delivery expansion to Miami, the world’s foremost market in the floral industry.

Miami is one of seven cities across the U.S. to benefit from UrbanStems’ same-day delivery expansion and the fourth market it has expanded to in the last six months. To celebrate the Miami same-day expansion, the company is unveiling an exclusive, limited edition floral design, called the “Flamingo Bouquet,” available through February 4, 2024.

“This investment comes at a pivotal time as we expand our same-day delivery service to cities across the U.S.,” said Meenakshi Lala, Chief Executive Officer at UrbanStems. “We are excited to continue the momentum of rapid growth in our same-day delivery experience in 2024 and kick-off this year by bringing our modern floral designs to the people of Miami. Looking ahead this year, we have plans to open additional same-day markets and  introduce more customers to our unparalleled gifting experience with best in class designs, delivery and customer satisfaction.”

UrbanStems’ same-day service is a key differentiator in the luxury floral industry and will play a dynamic role in evolving Miami’s reputation as a top global floral market. Most recently, the company added the same-day service to Atlanta and Chicago in late 2023, in addition to its legacy markets of Washington, D.C., Los Angeles, New York City, and Jersey City. The luxury floral delivery startup plans to continue its expansion to additional same-day markets this year.

“UrbanStems focuses on providing gift givers with an easy and fast digital experience that they can trust will inspire, surprise and delight gift recipients nationwide with chic, innovative fresh floral arrangements dreamt up by some of New York’s most talented designers,” said Aaron Pollock, Senior Finance Lead and UrbanStems Board Member. “We are honored to continue investing in and supporting the brand as it builds out its same-day footprint, and proud that the company has sent happy and memorable experiences to more than 10 million customers so far, with many more to come.”

Miami-area customers can use this exclusive link to purchase The Flamingo Bouquet and shop the same-day delivery experience. Browse more bouquets at www.urbanstems.com.

About UrbanStems
UrbanStems was founded in 2014 as a disruptive same-day e-commerce alternative to the traditional flower delivery companies. Today, the brand delivers same-day modern floral designs and on-trend gifts to seven major metropolitan cities, including Washington, D.C., Los Angeles, New York City, Jersey City, Chicago, Atlanta, and Miami, and coast-to-coast next-day delivery. For more information, please visit urbanstems.com.

Media Contact: 
Megan Darmody
[email protected]

SOURCE UrbanStems

Funding allows advancement of diverse programs through multiple clinical data readouts, including multiple indications for lead candidate felzartamab

SOUTH SAN FRANCISCO, Calif., Jan. 4, 2024 — Human Immunology Biosciences (HI-Bio^™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.

“These funds allow us to advance felzartamab, our clinically differentiated lead therapeutic candidate, through clinical readouts in multiple indications and preparation for registrational studies,” said Travis Murdoch, M.D., CEO of HI-Bio. “We are encouraged by promising clinical data to date for felzartamab and its anti-CD38 cell depletion approach, and we look forward to new data, including Phase 2 results from an investigator-initiated trial for antibody-mediated rejection in kidney transplant patients.” 

Since the company’s launch, HI-Bio has advanced felzartamab, a monoclonal antibody targeting CD38 and in-licensed from MorphoSys, across indications including antibody-mediated rejection (AMR), IgA nephropathy (IgAN), lupus nephritis (LN) and primary membranous nephropathy (PMN). Felzartamab has received Breakthrough Therapy Designation and Orphan Drug Designation from the U.S. Food and Drug Administration in PMN. HI-Bio has also initiated a clinical study of HIB210, an anti-C5aR1 candidate targeting neutrophil activation and chemotaxis.

“Immune-mediated diseases contribute to an immense disease burden which drives the need for novel targeted treatments to improve on existing therapies,” said Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global. “HI-Bio is generating compelling clinical data demonstrating the differentiated potential of felzartamab; we look forward to continued progress for felzartamab across multiple indications with high unmet need.”

Funding from the Series B will be used to advance clinical development of felzartamab, to evaluate the clinical properties of HIB210 in healthy volunteers and to advance a discovery-stage program targeting mast cell dysfunction toward IND-enabling studies. In conjunction with the financing, the company announced that Chris Dimitropoulos, Managing Director of Healthcare Investments at Alpha Wave Global, has been appointed to the HI-Bio Board of Directors.

About HI-Bio 
Human Immunology Biosciences, Inc. (HI-Bio^™) is a clinical-stage biotechnology company focused on discovering and developing precision medicines for people suffering from immune-mediated diseases (IMDs). HI-Bio is leading clinical immunology into its next chapter by targeting cellular drivers of disease. To learn more about HI-Bio, visit us at www.hibio.com or follow us on LinkedIn and Twitter.

SOURCE HI-Bio

US$1bn target total raise across both funds by end of 2024

NEW YORK, Jan. 4, 2024 — Omni Bridgeway is pleased to announce the first close of capital raising for the second series of its core funds, Fund 4 and Fund 5.

Existing investors (refer to OBL’s prior ASX announcement) in Fund 4 and Fund 5 have exercised their right to reinvest in Series II on the same terms.

The continued reinvestment by existing investors of the first and second generation funds underscores the confidence of leading institutional and legal finance investors in Omni Bridgeway’s track record, investment origination, and underwriting process.

The company anticipates further closings over the next 12 months to build up to the capped size of US$1bn across both funds and Omni Bridgeway will continue to be a 20% co-investor. This further capital raising will be aimed at broadening our private capital investor base.

Raymond van Hulst, Managing Director and CEO, commented, “We have achieved an important milestone with this first close of our Series II capital raise. Our valued capital partners are amongst the most reputable and experienced investors in legal finance. Their ongoing support and our continued access to capital is a strong endorsement of our platform and long-term performance track record, particularly given the current private capital landscape.”

“This will mark the first time our core funds have been open to new investors in almost six years, supporting our strategy of further diversification,” said Mr van Hulst.

ABOUT OMNI BRIDGEWAY

Omni Bridgeway is the global leader in legal finance and risk management, including dispute and litigation finance from case inception to post-judgment enforcement and recovery. Listed on the ASX, Omni Bridgeway operates from 26 international locations.

CONTACT:

Steven Savage| Senior Manager, Marketing and Communications +44 (0) 7951499 052| [email protected]

SOURCE Omni Bridgeway

BANGKOK, Jan. 4, 2024 — UniFAHS, a trailblazing biotechnology company specialising in phage technology for sustainable agriculture and food safety, today announced it has raised over USD 1.4 million in its seed funding round. This significant step propels the company forward in its mission of growth and transforming food production using environmentally friendly and sustainable approaches.

The funding round, led by A2D Ventures and supported by contributions from Asian Development Bank Ventures (ADB Ventures) and InnoSpace (Thailand), underscores the strong confidence in UniFAHS’s innovative approach and future potential. A2D Ventures is a prominent community-led early-stage investing platform that aims to tackle fragmentation and democratise access to investment opportunities.

“We are thrilled to lead and syndicate this strategic investment opportunity in UniFAHS, recognising the synergies between their groundbreaking technology and the founders’ scientific prowess. This investment underscores our confidence in Thai founders and Thailand-based startups’ potential to redefine and recreate industries, offering solutions that can be exported to global markets and achieve substantial growth quickly,” says Ankit Upadhyay, Founder and CEO of A2D Ventures.

Co-founded by Dr Kitiya Vongkamjan, a distinguished Cornell University alumna and leading figure in phage research and food safety, and Chalita Wongpukdee, who brings expertise in agribusiness marketing and sales with extensive connections in agriculture, food, feed, and animal health, UniFAHS’s patented phage solutions are at the forefront of combating antimicrobial resistance (AMR) and promoting climate-friendly agricultural practices. Dr Vongkamjan shares, “Our vision at UniFAHS is to create a sustainable future for food production. This funding is a financial boost and a strong endorsement of our phage technology’s potential to revolutionise the agriculture and food safety sectors.”

Recognised as one of the Top 10 Livestock Management startups globally by StartUs Insights in 2023, Dr Vongkamjan and her team continue to further groundbreaking research and sustainable food production to redefine the biotechnology landscape. This investment serves as a catalyst that will enable the company to expand its production capacity and extend its reach across Southeast and South Asia by working closely with its distribution partners to expand the customer segments by 20% in 2024 to impact the world’s food production significantly.

As UniFAHS embarks on a journey of growth and expansion, ADB Ventures has emerged as a critical partner, contributing financial support and a wealth of experience and global connections – with both companies sharing a united commitment to prioritising environmentally friendly and socially responsible practices in the pursuit of economic growth.

“UniFAHS’s innovative solutions represent a transformative opportunity in the agriculture and food sectors, significantly reducing our dependence on antibiotics. We believe UniFAHS has the potential to make a considerable impact on the climate in the region. We are enthusiastic about supporting UniFAHS’s expansion across Asia,” expressed Thitirat Sittakaradej, Investment Specialist at ADB Ventures.

To date, UniFAHS has successfully secured partnerships with the world’s top poultry producers in the region. By harnessing the power of phages, UniFAHS offers a game-changing approach to addressing pressing challenges for bacterial control and tackling antimicrobial resistance issues in agriculture and animal health.

InnoSpace (Thailand) also emphasised its strategic commitment: “Our investment in UniFAHS is driven by a commitment to fostering sustainable solutions for global challenges. We are excited to support UniFAHS’s journey to empower the team to expedite developing and deploying its cutting-edge phage solutions.”

Join Our Journey:

• For more information, visit https://unifahs.com/.
• For the latest developments, follow us on X (@Phage_UniFAHS) and LinkedIn (@UniFAHS).
• For investor enquiries, please get in touch with Dr Kitiya Vongkamjan at [email protected].

About UniFAHS

UniFAHS is a pioneer in applying phage technology, ensuring the sustainable production of safe foods from farm to fork, promoting the holistic concept of “One Health”, and actively combating the global challenge of antimicrobial resistance. The company is dedicated to shaping a brighter and more sustainable future through cutting-edge phage technology to enhance the well-being of communities and ecosystems as a “One-Health” approach.

Photo – https://mma.prnewswire.com/media/2310955/image.jpg

SHANGHAI and GEMBLOUX, Belgium and HEIDELBERG, Germany, Jan. 3, 2024 — Full-Life Technologies (“Full-Life”), a fully integrated global radiotherapeutics company, today announced the completion of $63.3 million financing, comprised of $47.3 million in Series B equity financing and $16 million in loan facilities. The financing will advance development of the Company’s radiopharmaceutical pipeline and manufacturing capabilities, as well as optimize its proprietary discovery platform, UniRDC^TM. With completion of such financing, Full-Life has secured more than $110 million funding since its inception in August 2021, including equity financing, loan facilities, and government subsidies.

The $47.3 million Series B equity financing was co-led by Prosperity7 Ventures and an undisclosed healthcare specialist investor, along with new investors Sky9 Capital, Summer Capital, and GuanghuaWutong Fund, as well as existing shareholders Chengwei Capital, HongShan, and Junson Capital. The $16 million loan facilities, secured in conjunction with the Series B equity financing, provide Full-Life with a flexible financing solution for the Company’s pipeline development and construction of the radiopharmaceutical manufacturing plant in Belgium.

“Cancer remains a formidable global challenge, causing immense suffering and loss,” said Aysar Tayeb, Executive Managing Director of Prosperity7 Ventures. “Full-Life is dedicated to addressing this issue within the field of Radionuclide Drug Conjugates (RDC) by leveraging its exceptional vector and linker design capabilities, as well as its expertise in radionuclides. Through its UniRDC^TM platform, Full-Life has the potential to extend its therapeutic indications to a wider range of cancers. We eagerly anticipate the future advancements of Full-Life, as it strives to deliver differentiated and superior solutions that will significantly improve the outcomes and quality of life for cancer patients.”

“The financing reflects strong support from our new and existing investors of our strategy and faith in the significant progress we have made in just over two years to build a fully integrated radiopharmaceutical company,” said Julie Wu, Chief Financial Officer of Full-Life. “The funding will support our evolution into a clinical-stage company, the advancement of our pipeline programs, and the construction of a Good Manufacturing Practices (GMP) manufacturing facility.”

Since completion of its Series A equity financing in 2022, Full-Life has achieved multiple significant milestones, including but not limited to: 

• Advancing the Company’s lead drug candidate, ²²⁵Ac-FL-020, towards Phase I clinical trials in metastatic castration-resistant prostate cancer (mCRPC) patients. Clinical trials are planned to start in both Europe and the U.S. in early 2024. Full-Life’s PSMA-targeting vector, FL-020, is specifically designed to deliver the highly potent alpha-emitter, Actinium-225.
• Assembling a strong pre-clinical portfolio including both first-in-class and best-in-class programs as well as development of the novel UniRDC^TM discovery platform. UniRDC^TM is a proprietary platform established to streamline the discovery process of RDC.
• Acquiring a 17,000 square meter of land in the Walloon region of Belgium, obtaining the required construction permit, and beginning construction of a 4,000 square meter state-of-the-art GMP-level radiopharmaceutical production facility. The facility is designed to advance Full-Life’s end-to-end solution and manufacture a broad spectrum of radiopharmaceuticals.

About ²²⁵Ac-FL-020

²²⁵Ac-FL-020 is a novel, next-generation PSMA radioligand candidate currently being developed for the treatment of mCRPC. Its targeting vector, FL-020, was discovered using Full-Life’s proprietary Clear-X^TM linker technology, which enables significant improvement of drug uptake at the tumor while maintaining fast systemic clearance. In pre-clinical models, ²²⁵Ac-FL-020 has demonstrated promising anti-tumor activity.

About UniRDC^TM

UniRDC^TM is a proprietary discovery platform, which rationalizes and accelerates the discovery process of RDC drug candidates. UniRDC^TM enables a short discovery timeline of 18 months or less from a target to an RDC development candidate with human biodistribution data, which has been repeatedly validated internally. UniRDC^TM covers a range of modalities including small molecule, cyclic peptide, and nanobody. It is centered on a rich set of proprietary synthetic chemistry and protein engineering tool kits, including Clear-X™ linker technology and Res-X™ modification methods. Such tool kits have been proven to be essential to rapidly turn an affinity matured binder to a development candidate with a therapeutically optimal biodistribution profile. Details of the platform can be found at: https://www.full-life.com/radio/unirdc 

About Full-Life Technologies

Full-Life Technologies Limited (“Full-Life”) is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We seek to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.

About Prosperity7

Prosperity7 Ventures (P7) is the diversified growth fund of Aramco Ventures, a subsidiary of Aramco, the world’s leading integrated energy and chemicals company. The fund’s name derives from “Prosperity Well’, the 7th oil well drilled in Saudi Arabia and the first to strike oil. Taking forward this pioneering history, P7 invests globally with a long-term view in breakthrough technologies and transformational business models that will bring prosperity and positive impact on a vast scale.

https://www.prosperity7vc.com/ 

Follow us:

Website: www.full-life.com 

SOURCE Full-Life Technologies

NEW YORK, Jan. 3, 2024 — Banner Ridge Partners, a $7.3 billion multi-strategy private equity investment firm, has completed fundraising for Banner Ridge Secondary Fund V (“BRP V”) at its hard cap with $2.15 billion of total commitments. BRP V is the latest fund to be raised as part of the firm’s flagship secondary program. The Fund was oversubscribed, receiving capital commitments from a wide range of institutional investors, including pension funds and several prominent family offices. This is the fifth fundraise since the firm became an independent business in June 2019.

Since the strategy’s inception in 2010 at its prior firm, the Partners at Banner Ridge have committed over $3.0 billion to over 150 discrete managers focused on distressed, special situations, and credit strategies globally. Through primary, secondary, and co-investments with specialist private equity sponsors in its target market, Banner Ridge will focus on investing in a subset of the market characterized by both complexity and limited access to information.

Anthony Cusano, Co-Founder and Portfolio Manager, said, “Higher interest rates and a lack of liquidity in the market paired with greater acceptance of secondaries as a portfolio management tool is driving exceptional opportunities for us. We have continuously expanded our investment team to include a broad array of skills, which has led to increased deal flow and better access to information, allowing us to make more informed investment decisions. We are well positioned to take advantage of the opportunities that arise from being a distressed, special situations, and credit specialist. C.J. Driessen, Co-Founder, added, “We have made several investments in the Fund and continue to make progress on a robust pipeline of opportunities that align squarely with our proven secondary investment strategy. We are grateful to have been entrusted by an exceptional group of investors and we look forward to continuing our long-term track record of outperformance on their behalf.”

Banner Ridge Partners:

Banner Ridge Partners is a $7.3 billion alternative investment specialist that identifies best-in-class private equity managers in niche markets. The Firm manages discrete investment vehicles for primary, co-investment, and secondary investment strategies. Banner Ridge is led by a senior team with significant private markets experience. By targeting deep value opportunities, focusing on fragmented markets, and working through structural complexities, we believe we can exceed the investment goals of our clients. To learn more about Banner Ridge, please visit www.BannerRidge.com.

Media contact: 
Anthony Cusano
Managing Partner
212.265.4240

SOURCE Banner Ridge Partners